Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Hafsah Nabi; Bente Glintborg; AG Loft; O Hendricks; JK Pedersen; SA Just; Rabiah Ahmed; Kamilla  Danebod; HL Munk; A Colic; A Linauskas; Dorte Vendelbo Jensen; LB Christensen; Natalia Manilo; N Lomborg; S Kristensen; F Mehnert; NS Krogh; Merete Lund Hetland

Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Hafsah Nabi, Bente Glintborg, AG Loft, O Hendricks, JK Pedersen, SA Just, Rabiah Ahmed, Kamilla Danebod, HL Munk, A Colic, A Linauskas, Dorte Vendelbo Jensen, LB Christensen, Natalia Manilo, N Lomborg, S Kristensen, F Mehnert, NS Krogh, Merete Lund Hetland

Department for Rheumatology and Spine Diseases

Original language	English
Article number	OP16
Book series	Scandinavian Journal of Rheumatology, Supplement
Volume	50
Issue number	130
Pages (from-to)	14-5
Number of pages	2
ISSN	0301-3847
Publication status	Published - 2021

Cite this

Nabi, H., Glintborg, B., Loft, AG., Hendricks, O., Pedersen, JK., Just, SA., Ahmed, R., Danebod, K., Munk, HL., Colic, A., Linauskas, A., Jensen, D. V., Christensen, LB., Manilo, N., Lomborg, N., Kristensen, S., Mehnert, F., Krogh, NS., & Hetland, M. L. (2021). Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology, Supplement, 50(130), 14-5. Article OP16.

Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. / Nabi, Hafsah ; Glintborg, Bente; Loft, AG et al.
In: Scandinavian Journal of Rheumatology, Supplement, Vol. 50, No. 130, OP16, 2021, p. 14-5.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Nabi, H , Glintborg, B, Loft, AG, Hendricks, O, Pedersen, JK, Just, SA, Ahmed, R, Danebod, K, Munk, HL, Colic, A, Linauskas, A, Jensen, DV, Christensen, LB, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, NS & Hetland, ML 2021, 'Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry', Scandinavian Journal of Rheumatology, Supplement, vol. 50, no. 130, OP16, pp. 14-5.

Nabi H , Glintborg B, Loft AG, Hendricks O, Pedersen JK, Just SA et al. Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology, Supplement. 2021;50(130):14-5. OP16.

Nabi, Hafsah ; Glintborg, Bente ; Loft, AG et al. / Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. In: Scandinavian Journal of Rheumatology, Supplement. 2021 ; Vol. 50, No. 130. pp. 14-5.

@article{109ecceb157041dc81755f0822248cab,

title = "Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry",

author = "Hafsah Nabi and Bente Glintborg and AG Loft and O Hendricks and JK Pedersen and SA Just and Rabiah Ahmed and Kamilla Danebod and HL Munk and A Colic and A Linauskas and Jensen, {Dorte Vendelbo} and LB Christensen and Natalia Manilo and N Lomborg and S Kristensen and F Mehnert and NS Krogh and Hetland, {Merete Lund}",

note = "COPECARE",

year = "2021",

language = "English",

volume = "50",

pages = "14--5",

journal = "Scandinavian Journal of Rheumatology, Supplement",

issn = "0301-3847",

publisher = "Taylor & Francis A B",

number = "130",

}

TY - ABST

T1 - Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

AU - Nabi, Hafsah

AU - Glintborg, Bente

AU - Loft, AG

AU - Hendricks, O

AU - Pedersen, JK

AU - Just, SA

AU - Ahmed, Rabiah

AU - Danebod, Kamilla

AU - Munk, HL

AU - Colic, A

AU - Linauskas, A

AU - Jensen, Dorte Vendelbo

AU - Christensen, LB

AU - Manilo, Natalia

AU - Lomborg, N

AU - Kristensen, S

AU - Mehnert, F

AU - Krogh, NS

AU - Hetland, Merete Lund

N1 - COPECARE

PY - 2021

Y1 - 2021

M3 - Conference abstract in journal

SN - 0301-3847

VL - 50

SP - 14

EP - 15

JO - Scandinavian Journal of Rheumatology, Supplement

JF - Scandinavian Journal of Rheumatology, Supplement

IS - 130

M1 - OP16

ER -